Dr Yvette Kasamon presents the results of a recent study on blood and bone marrow transplanation at the 2013 ASH Annual Meeting.

To more fully demonstrate the utility of haploidentical bone marrow or peripheral blood stem cell transplants (haploBMT) as an alternative to fully matched transplants, this study evaluated nonmyeloablative, related haploBMT (with post-transplantation cyclophosphamide) among patients aged 50 – 75 with poor-risk haematologic malignancies.